Nanocarrier-mediated cancer therapy with cisplatin: A meta-analysis with a promising new paradigm

• Main Authors: Ranasinghe, Ranmali, Mathai, Michael, Alshawsh, Mohammed Abdullah, Zulli, Anthony
• Format: Article
• Published: Elsevier 2024
• Subjects: R Medicine
• Online Access: http://eprints.um.edu.my/45315/; https://doi.org/10.1016/j.heliyon.2024.e28171

Aims: Cisplatin is a frontline chemotherapeutic utilized to attenuate multiple cancers in the clinic. Given its side -effects, a new cisplatin formulation which could prevent cytotoxicity, metabolic deficiencies and metastasis is much needed. This study investigates whether nanocarriers can provide a better mode of drug delivery in preclinical cancer models seeking a potent anticancer therapeutic agent. Materials and methods: The PubMed database was searched, and 242 research articles were screened from which 94 articles qualified for selection from those published by December 31, 2023 and the data was synthesized using the Review Manager software. Key findings: Cisplatin encapsulated as a nanomedicine confirmed the versatility of nanocarriers in significantly diminishing cancer cell viability, half maximal inhibitory concentration, tumour volume, biodistribution of platinum in tumours and kidney; at p < 0.00001 and a 95% confidence interval. Significance: An estimated 19.3 million global cancer incidence is reported with 50% mortality worldwide for which nanocarrier-mediated cisplatin therapy is most promising. Our findings offer new vistas for future cancer treatment when combined with chemo-immunotherapy that utilizes the recently advanced nanozymes.